ÂÜÀòÂÒÂ×

Hao-Ming Chang, Ph.D. has a diverse and extensive work experience spanning several companies and research areas. Their most recent position is as the Senior Director of Preclinical Research at Cytovia Therapeutics, where they provide strategic leadership and oversees preclinical research activities. Hao-Ming previously served as the Director of Preclinical Research at the same company.

Prior to Cytovia Therapeutics, Hao-Ming worked at NantKwest as a Scientist, Principal, contributing to scientific research and development.

Hao-Ming also held positions at several pharmaceutical and biotech companies, including Alexion Pharmaceuticals, Inc., where they worked as a Research Scientist II. In this role, they supervised and mentored other scientists and led innovative projects in cell-based screening assay development and organ-on-a-chip collaborative projects.

At Synageva BioPharma Corp., Hao-Ming worked as a Senior Research Scientist, leading a team and developing novel primordial germ cell (PGC) technology. Hao-Ming also established a stem cell/targeted genome editing team.

Hao-Ming's experience also includes roles at EMD Serono, Inc., Agios Pharmaceuticals, Children's Hospital Boston/Harvard Medical School, New York University Medical Center, and Taipei Mackay Memorial Hospital. In these positions, they conducted research in various areas such as translational oncology, small molecule therapeutics, microRNA function, stem cell biology, epigenetics, and cytokine signal transduction.

Overall, Hao-Ming Chang, Ph.D. has a strong background in scientific research, leadership, and innovation, contributing to advancements in various fields of biotechnology and pharmaceuticals.

Hao-Ming Chang, Ph.D. holds a Ph.D. degree in Molecular Oncology and Immunology from New York Medicine Jobs. Prior to that, they completed a Master of Science (M.S.) in Recombinant DNA Biotechnology at New York University. Hao-Ming earned their Bachelor of Science (B.S.) in Molecular Biology and Biochemistry from National Tsing Hua University.